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Molecular Medicine
MicroRNA-29 in Aortic Dilation: Implications for
Aneurysm Formation
Short Communication
Reinier A. Boon, Timon Seeger, Susanne Heydt, Ariane Fischer, Eduard Hergenreider,
Anton J.G. Horrevoets, Manlio Vinciguerra, Nadia Rosenthal, Sergio Sciacca, Michele Pilato,
Paula van Heijningen, Jeroen Essers, Ralf P. Brandes, Andreas M. Zeiher, Stefanie Dimmeler
Rationale: Aging represents a major risk factor for coronary artery disease and aortic aneurysm formation.
MicroRNAs (miRs) have emerged as key regulators of biological processes, but their role in age-associated
vascular pathologies is unknown.
Objective: We aim to identify miRs in the vasculature that are regulated by age and play a role in age-induced
vascular pathologies.
Methods and Results: Expression profiling of aortic tissue of young versus old mice identified several age-
associated miRs. Among the significantly regulated miRs, the increased expression of miR-29 family members
was associated with a profound downregulation of numerous extracellular matrix (ECM) components in aortas
of aged mice, suggesting that this miR family contributes to ECM loss, thereby sensitizing the aorta for aneurysm
formation. Indeed, miR-29 expression was significantly induced in 2 experimental models for aortic dilation:
angiotensin II-treated aged mice and genetically induced aneurysms in Fibulin-4R/R mice. More importantly,
miR-29b levels were profoundly increased in biopsies of human thoracic aneurysms, obtained from patients with
either bicuspid (n79) or tricuspid aortic valves (n30). Finally, LNA-modified antisense oligonucleotide-
mediated silencing of miR-29 induced ECM expression and inhibited angiotensin II-induced dilation of the aorta
in mice.
Conclusion: In conclusion, miR-29-mediated downregulation of ECM proteins may sensitize the aorta to the
formation of aneurysms in advanced age. Inhibition of miR-29 in vivo abrogates aortic dilation in mice,
suggesting that miR-29 may represent a novel molecular target to augment matrix synthesis and maintain
vascular wall structural integrity. (Circ Res. 2011;109:1115-1119.)
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Age is one of the major risk factors for cardiovasculardiseases. With increasing life expectancy, the preva-
lence of aging-associated cardiovascular diseases will even
increase in the near future.1 One particular age-associated
disease is abdominal aortic aneurysm formation, which af-
fects approximately 9% of elderly men and has a high
mortality rate.2 On the other hand, aneurysms in the ascend-
ing part of the thoracic aorta are less age-associated and are
often the result of genetic defects involving extracellular
matrix (ECM) components.3 On a mechanistic level, analysis
of human pathological sections revealed that aneurysm for-
mation and rupture are characterized by thinning of the
vascular wall and blood vessel dilation.4 Decreased formation
and/or increased degradation of ECM are believed to be the
key pathophysiological processes leading to vascular wall
thinning.5,6
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MicroRNAs (miRs) have recently emerged as key regula-
tors of several (patho-) physiological processes. MiRs are
short noncoding RNAs that regulate protein expression by
inducing degradation of the targeted mRNA or by blocking
protein translation. Whereas various studies showed that
specific miRs control vessel growth and cardiac function,7 the
involvement of miRs in aortic wall pathologies are less well
known.
Methods
Comprehensive methods are available as an Online Supplement at
http://circres.ahajournals.org.
Results
miRs Are Affected by Aging in the Aorta
miR and mRNA microarray expression profiles comparing
aortas of aged with young mice revealed 18 miRs that are
regulated (fold increase/decrease 1.5 and P0.01) (Fig-
ure 1A and Online Table I). To establish which of these
miRs affect mRNA expression changes, we used 2 distinct
unbiased bioinformatics tools that use mRNA expression
data to identify putative regulation by miRs. Both these
tools, Sylamer8 and MirExTra,9 identified the miR-29
family (miR-29a, b, and c) to be the only 1 of the 18
regulated miRs to functionally affect mRNA levels (Figure
1B and 1C). The upregulation of the miR-29 family by age
in aortic tissue was confirmed by real-time PCR (Figure
1D). The miR-29 family is transcribed as 2 bicistronic
primary miRs (Figure 1E). We found that only the pri-
miR-29b1/a cluster is transcriptionally induced by aging
(Figure 1F), suggesting that miR-29 family members are
increased by both transcriptional and post-transcriptional
mechanisms. Together, these data indicate that miR-29 is
the only age-regulated miRNA, which significantly affects
mRNA expression levels in the aorta.
Non-standard Abbreviations and Acronyms
Ang-II Angiotensin II
ECM extracellular matrix
LNA locked nucleic acid
miR microRNA
RT-PCR real time PCR
Figure 1. Aging regulates various miRs.
MicroRNA and mRNA microarray profiles
of aortas of aged (18 months old, n4)
and young mice (6 weeks old, n4). A,
M/A plot of the miRNA array data. Hybrid-
ization probes for upregulated miRs
(P0.01) are shown in red and for down-
regulated miRs (P0.01) in green. mRNA
profiling data were used to calculate
enrichment of putative seed target
sequences in the 3UTR of genes that are
regulated by aging, either with Sylamer
(B) or mirExTra (C). RT-PCR of miR-29
levels in aortas (D) (n8). E, miR-29
genomic organization. F, RT-PCR of pri-
mary miR-29 clusters in aortas of young
and aged mice (n5).*P0.05, #P0.07.
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MiR-29 Is Induced in Aortic Dilation
and Aneurysms
In the heart, the miR-29 family has been shown to control
tissue fibrosis after acute myocardial infarction by targeting
mRNA coding for ECM proteins such as collagens, fibrillin
and elastin.10 All of these known targets of miR-29 were
downregulated by age in the aorta (Figure 2A and Online
Table II), including elastin, recently described to be crucially
regulated by miR-29 in aortic development.11 Because re-
duced ECM expression is a hallmark of aneurysm forma-
tion,6,12 and age is the major risk factor for abdominal aortic
aneurysm formation,2 we hypothesized that the induction of
miR-29 may link aging to aneurysm formation. Therefore, we
next studied the role of miR-29 in 18-month-old mice that
were infused with angiotensin II (Ang-II) for 1 week to
induce aortic dilation in vivo. Ang-II infusion significantly
increased the expression of miR-29b in the aorta, whereas
miR-29a and miR-29c were not affected (Figure 2B).
Because defects in ECM components also contribute to the
formation of inherited aneurysms, we next evaluated whether
miR-29 family members are also regulated in the genetically
induced thoracic aortic aneurysms that develop due to ECM
defects in Fibulin-4R/R knockdown mice.13 Fibulin-4R/R mice
demonstrated a profound increase in expression of all 3
miR-29 family members in the aortic arch as compared to
wild-type littermates (Figure 2C).
Finally, we analyzed the expression of miR-29a, b, and c in
aortic biopsy samples obtained from a large series of patients
with a thoracic aortic aneurysm undergoing aortic valve
replacement surgery. The patients were divided into 2 groups,
patients with a bicuspid aortic valve and patients with a
tricuspid aortic valve, and were compared to control subjects
without a thoracic aortic aneurysm, who underwent coronary
bypass surgery (Online Table III). The expression of miR-29b
is significantly increased in both aneurysm patient groups as
compared to control subjects, whereas miR-29a and miR-29c
are not affected (Figure 2D).
Inhibition of miR-29 In Vivo Prevents Ang II-
Induced Dilation of the Aorta in Aged Mice
In order to assess whether miR-29 expression is causally
linked to aortic dilation, we next designed LNA-modified
antisense oligonucleotides14 (LNA-29) to silence the expres-
sion of miR-29 in vivo. LNA-29 dose-dependently inhibited
miR-29a, b, and c expression (Figure 3A), whereas it did not
affect the expression of its closest homologues (Online Figure
I). LNA-29 significantly increased expression of the miR-29
targets Col1A1, Col3A1, and elastin in aortic tissue (Figure
3B, Online Figure I). To determine whether inhibition of
miR-29 prevents aortic dilation, we treated 18-month-old
mice with Ang-II and measured the diameter of the aorta
proximal to the origin of the renal arteries by ultrasonography
before treatment and 7 days after. LNA-29 potently inhibited
the expression of miR-29 in the aorta, even during continuous
Ang-II infusion (Online Figure II), and induced a concomi-
tant increase in protein levels of the miR-29 target elastin
(Figure 3C, Online Figure III). LNA-29 abrogated the Ang-
II-mediated increase in aortic diameter, whereas the aorta
significantly dilated in the PBS- and control LNAotreated
groups, as compared to untreated mice (Figure 3D). Likewise,
aortic dilation in Ang-II–infused 6-month-old ApoE/ mice
was reduced by LNA-29 treatment at 1 week (Online Figure
IV and V). Blood pressure was unaffected by miR-29
silencing, indicating that the lack of aortic diameter increase
in Ang-II/LNA-29 cotreatment is not due to indirect effects
on blood pressure (Online Figure VI). MiR-29 is known to
regulate fibrosis in the heart, liver, and kidney.10 However,
LNA-29 did not affect cardiac function (data not shown) and
Figure 2. Increased expression levels
of miR-29 in aneurysms. A, RT-PCR in
entire aortas of young and aged mice
(n8) (A), in entire aortas of PBS-treated
and Ang-II treated (1 mg/kg/d) mice
(n8) (B) and in aortic arches of
Fibulin-4 mutant mice and wild-type lit-
termates (n3) (C). RT-PCR for miR-29
in human aorta biopsies (D).*P0.05,
#P0.1.
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liver or kidney fibrosis, as investigated by histological anal-
ysis (Online Figure VI).
Discussion
Here, we demonstrate that vascular aging and age-associated
pathologies induce a significant upregulation of the miR-29
family in the aorta of mice and humans. Whereas aging and
genetically induced aneurysms were associated with in-
creased expression of all family members, miR-29b was
preferentially upregulated in Ang-II–induced aortic dilation
in mice and in human thoracic aortic aneurysm biopsies. The
upregulation of the miR-29 family in aging is consistent with
a recent report, showing an increased expression of all
miR-29 family members in an accelerated aging model in
mice.15
MiR-29 targets several ECM proteins, which are known to
play a key role in maintaining the integrity of the vascular
wall. MiR-29 was additionally shown to induce apoptosis in
cancer cells by targeting Mcl-1, an antiapoptotic Bcl-2 family
member,16 and by augmenting p53 levels.17 Smooth muscle
cell apoptosis is considered to favor aneurysm formation18
and, because miR-29 is highly expressed in smooth muscle
cells (Online Figure V and VII), this mechanism may con-
tribute to miR-29–mediated destabilization of the vascular
wall. Interestingly, inhibition of miR-29 decreased the ex-
pression of matrix metalloproteinase MMP9 in the aorta
(Online Figure VIII), which may additionally prevent further
degradation of matrix proteins. However, whereas miR-29
inhibition also blocked the early dilation in the Ang-II-
induced aneurysm model in ApoE/ mice (Online Figure
IV), it did not prevent aneurysm formation in this rapidly
accelerated inflammatory model at 4 weeks suggesting that
inhibition of miR-29 predominantly maintains the structural
integrity of the vessel wall.
In conclusion, aging and miR-29 repress the expression of
target genes that mainly encode ECM proteins and may, thus,
sensitize the aorta for aneurysm formation (Figure 3E). Local
inhibition of miR-29, eg, by drug-eluting balloons or stents,
may provide a promising novel therapeutic approach to
interfere with vascular aging by augmenting matrix synthesis.
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Novelty and Significance
What Is Known?
● Advanced age is a major risk factor for developing aneurysms.
● MicroRNA-29 inhibits expression of several extracellular matrix
proteins.
What New Information Does This Article Contribute?
● Advanced age induces microRNA-29 expression in the aorta and
represses extracellular matrix expression.
● MicroRNA-29 levels are increased in the aorta in animal models of
aneurysm formation and patients with thoracic aneurysms.
● Inhibition of microRNA-29 in vivo prevents aortic dilatation in mice.
Aging is a major risk factor for aneurysm formation. Because
microRNAs play pivotal roles in various physiological processes, we
assessed changes in the microRNA expression profile in the aorta in
aged mice. MicroRNA-29, which is known to attenuate extracellular
matrix expression, is induced in the aorta of old mice. Moreover,
microRNA-29 is induced in mouse models of aortic aneurysm and
human aneurysm biopsies. Inhibition of microRNA-29 prevents
aortic dilation in aged mice. Thus, inhibition of microRNA-29 may
constitute a promising treatment against aortic aneurysms.
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Supplement Material 
 
Supplemental Methods 
Laboratory animals, human material and LNA-antimirs  
C57BL/6 mice were obtained from Charles River (Sulzfeld, Germany) and Janvier (Le Genest 
Saint-Isle, France). Fibulin-4 mutant mice were described before 1. The animal experiments 
were approved by the Regional Board of the State of Hessen, Germany. Patient material was 
obtained under informed consent and according to the declaration of Helsinki. Atherosclerotic 
risk factors were determined as described before 2. Echography was performed using a Vevo-
770 (Visualsonics, Toronto, Canada) and aorta diameters were measured proximal of the renal 
arteries by a researcher blinded to the experimental procedure. Blood pressure measurements 
were performed with a Visitech 4 channel blood pressure analysis system (Visitech, Apex, 
NC).  LNA-antimirs were synthesized by Exiqon (Vedbaek, Denmark). The following 
sequences were used in this study: LNA-Co: ACGTCTATACGCCCA, Tm 75°C; LNA-29: 
GATTTCAAATGGTGCT, Tm 73°C. Angiotensin II was purchased from Bachem 
(Bubendorf, Switzerland), osmotic pumps from Durect (Cupertino, CA). 
 
RNA isolation, Real-time PCR, micro-arrays and bioinformatics 
Total RNA was isolated with miRNeasy and miRNeasy FFPE kits from Qiagen and real-time 
PCR was performed with Applied Biosystems (Carlsbad, CA) microRNA assays run on an 
Applied Biosystems StepOnePlus machine. SNO202 and RNU6 were used for normalization. 
Transcriptional profiling was performed by DNAvision (Charleroi, Belgium) on the Agilent-
v1 platform (570 miRs) or on the Affymetrix 430 v2.0 platform (mRNA, full genome). 
Microarray expression data are available at the NCBI Gene Expression Omnibus (GEO) 
(http://www.ncbi.nlm.nih.gov/project/geo). Data was background-corrected and normalized 
by quantile normalization. Statistical comparisons were done using a Bayesian one-way 
 at Vrije Universiteit--Amsterdam on April 3, 2012http://circres.ahajournals.org/Downloaded from 
ANOVA and probability-values were corrected for multiple testing with the 
Benjamini/Hochberg false discovery rate method. Sylamer analysis was performed with 
software from http://www.ebi.ac.uk/enright/sylamer/ using a genelist of microarray 
expression data sorted by regulation factor (fold change/p-value-0.5) and publicly available 
mouse 3’ UTR data (from Biomart). For DIANA mirExTra analysis 
(http://diana.cslab.ece.ntua.gr/hexamers), regulated gene lists (fold change<-1.5 and p-
value<0.05) and unchanged gene lists (fold change= -1.1 to 1.1) were used. Sylamer and 
mirExTra identify statistical enrichment in a ranked list, more specifically these tools identify 
combinations of nucleotides that are present in the 3’UTR of genes that are regulated. 
MirExTra uses target prediction software rather than random nucleotide combinations. 
 
Protein extraction and Western blots 
Extracellular proteins were extracted as previously described 3. In short, adventitial tissue was 
removed from mouse aortas and washed 5 times in PBS with 25mM EDTA. Then the aortas 
were vortexed at room temperature for 72h in 4M guanidine HCl, 50mM sodium acetate, 25 
mM EDTA, pH5.8. Proteins were then precipitated in 80% ethanol for 16h at -20°C and 
centrifugation. Pellets were washed with 90% ethanol, dried and resuspended in 
deglycosylation buffer (150mM NaCl, 50mM sodium acetate, 10mM EDTA, proteinase and 
phosphatase inhibitors, containing 0.05 units each of chondriotinase ABC, keratinase and 
heparitinase II (Sigma Aldrich, St. Louis, MO)). After 16h incubation at 37°C, each sample 
was boiled in denaturing sample buffer and loaded entirely on a single 8-16% polyacrylamide 
gradient gel (Thermo-Fischer). After separation, gels were blotted to PVDF membranes and 
total proteins were stained using PonceauS as loading control. The antibody used for Elastin 
was from Abcam (Cambridge, MA). 
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Statistics 
Data were analyzed with Graphpad Prism 5 using unpaired student’s t-tests when comparing 
two conditions, or a one-way ANOVA with Bonferroni or Newman-Keuls correction for 
multiple comparisons. Probability-values of less than 0.05 were considered significant and 
tests were performed two-sided. Correlations were analyzed using the Pearson method. 
Patient characteristics were assessed by Chi2-test. Data are presented as mean and error bars 
depict the standard error of the mean (SEM). 
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Online figure I
Expression of closest homologues of miR-29
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Online figure I. MiR-29 inhibition dose-dependently induces miR-29 targets, but 
does not affect the expression levels of close homologues of miR-29a, b and c.
Mice (8 weeks old) were treated intravenously with LNA-29 at 10, 20 or 40 mg/kg or 
with PBS. After 7 days, collagen 1A1, 3A1 and elastin were measured by RT-PCR 
(n=4) (A). (B) RT-PCR was performed with RNA isolated from mouse aortas, one 
week after a single intravenous injection of 20 mg/kg LNA-29 (designed to target 
miR-29) or scrambled control LNA (LNA-Co). MiR-29 homologues were identified 
by BlastN at mirbase.org. MiR-21 is a fibrosis-related miRNA. (n=4)
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Online figure II
miR-29 knockdown in aorta
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Online figure II. LNA-29 inhibits the expression of miR-29 in the aorta in 
Ang-II treated mice.
Real-time PCR was performed with RNA isolated from mouse aortas, four 
weeks after implantation of subcutaneous AngiotensinII-releasing minipump 
and weekly intravenous injection of PBS, 20 mg/kg LNA-29 (designed to 
target miR-29) or scrambled control LNA (LNA-Co). Untreated mice did not 
receive any intravenous injection nor AngII (n=4-10).
 at Vrije Universiteit--Amsterdam on April 3, 2012http://circres.ahajournals.org/Downloaded from 
Online figure III
PBS LNA-Co LNA-29
Elastin protein in aorta
0.0
0.5
1.0
1.5
2.5
2.0
Fo
ld
 C
ha
ng
e
*
Angiotensin II
Online figure III. Elastin protein expression in the aorta is induced by LNA-29 treatment.
18-month old mice were infused with Ang-II by subcutaneous mini-pumps (1 mg/kg/day) and 
received PBS, LNA-Co or LNA-29 intravenously at day 0 (20 mg/kg). After 7 days, aortas were 
harvested and extracellular proteins were extracted. Elastin levels were analyzed by Western blot 
and quantified by densitometry (using ImageJ). n=4 *p=0.046 (one-way ANOVA with LSD 
multiple comparison post-hoc test)
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Online figure IV. MiR-29 inhibition reduces AngII-mediated aorta dilation in ApoE-/- mice, without 
affecting inflammation.
The diameter of the aorta was measured in vivo by ultrasonography after 7 days of AngII infusion in ApoE-/- 
mice and untreated wild-type mice (A) or after 4 weeks of AngII infusion from aortic histology sections ex 
vivo (non-pressurized) (B) (n=8-19). Vessel wall T lymphocyte and macrophage burden were quantified in 
histology sections, with CD3 and CD68 stainings (C and D). *P<0.05
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Online figure V. MiR-29b is expressed in the vessel wall of Angiotensin II treated ApoE-/- mice.
In situ hybridization for miR-29b with double-DIG-labeled LNA detection probes on aorta tissue from 6 
month-old ApoE-/- mice that were treated with Angiotensin II and either PBS or LNA-29 for 4 weeks. 
Autofluorescence is depicted in green. The miR-29b or scrambled (non-specific) detection probe is visual-
ized in red. Yellow color indicates autofluorescent signal in both the green and red channels. (L) depicts the 
vessel lumen and (*) indicate autofluorescent internal elastic laminae.
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Online figure VI. LNA-29 treatment does not affect blood pressure, nor fibrosis, in combi-
nation with Angiotensin II infusion.
(A) Blood pressure was measured using tail-cuffs, 5 days after implantation of subcutaneous 
Angiotensin II-releasing minipump and a single intravenous injection of PBS, 20 mg/kg 
LNA-29 (designed to target miR-29) or scrambled control LNA (LNA-Co). Untreated mice did 
not receive any intravenous injection nor AngII. (n=6-8) (B) Liver and kidney sections were 
obtained from mice that received continuous Angiotensin II infusion and weekly treatment with 
intravenous PBS, LNA-Co (20 mg/kg) or LNA-29 (20 mg/kg) at 4 weeks after start of treat-
ment. Collagen was stained using Sirius Red.
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Online figure VII
Online figure VII. miR-29b expression levels in vascular cell types.
Real-time PCR was performed for miR-29b with RNA isolated from human 
aorta smooth muscle cells (white bar), human umbilical vein endothelial cells 
(grey bar) and human CD14+ cells isolated from peripheral blood mononu-
clear cells (black bar). *p<0.05
*
*
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Online figure VIII
Online figure VIII. LNA-29 reduces the expression of MMP9 but not 
MMP2 in the aorta.
Real-time PCR was performed for MMP2 and MMP9 with RNA isolated 
from mouse aortas, one week after a single intravenous injection of PBS, 20 
mg/kg LNA-29 (designed to target miR-29) or scrambled control LNA 
(LNA-Co) (n=5-8). #p=0.068
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Online table I. MicroRNAs that are regulated by age in the mouse aorta (absolute fold 
change>1.5 and p<0.01) 
  
Upregulated miRs Fold FDR p Role 
mmu-miR-146a 2.02 0.00671 Inflammation 
mmu-miR-142-3p 1.63 0.00599 Hematopoiesis 
mmu-miR-29b 1.61 0.00381 Fibrosis/apoptosis 
mmu-miR-223 1.58 0.00649 Hematopoiesis 
Downregulated miRs Fold FDR p Role 
mmu-miR-299* -2.21 0.00032 Unknown 
mmu-miR-181c -2.14 0.00028 Hematopoiesis 
mmu-miR-127 -2.10 0.00013 Lung development 
mmu-miR-154 -1.95 0.00145 Unknown 
mmu-miR-337-5p -1.86 0.00163 Unknown 
mmu-miR-379 -1.76 0.00150 Unknown 
mmu-miR-136 -1.71 0.00244 Unknown 
mmu-miR-329 -1.70 0.00017 Unknown 
mmu-miR-31 -1.67 0.00246 Oncogenesis 
mmu-miR-322 -1.67 0.00675 Angiogenesis/differentiation 
mmu-miR-377 -1.63 0.00359 Fibrosis 
mmu-miR-434-3p -1.61 0.00325 Unknown 
mmu-miR-411 -1.54 0.00052 Unknown 
mmu-miR-181d -1.51 0.00237 Hematopoiesis 
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Online table II Extracellular matrix expression is repressed by age in the aorta
Symbol fold change Bayes.p FDR GenBank UniGene Description
Fbn2 -6.0323876 0.00037421 0.013589 NM_010181 Mm.20271 fibrillin 2
Col1a1 -4.7324502 1.00E-06 0.000192 U08020 Mm.277735 procollagen, type I, alpha 1
Mmp16 -3.7790897 0.00024836 0.010372 BB378819 Mm.204820 matrix metallopeptidase 16
Col3a1 -3.4727743 3.52E-09 2.41E-06 AW550625 Mm.249555 procollagen, type III, alpha 1
Col1a2 -3.376066 1.32E-08 6.85E-06 BF227507 Mm.277792 procollagen, type I, alpha 2
Fbn2 -3.2689534 0.00084569 0.023661 AV010392 Mm.20271 fibrillin 2
Eln -3.0622485 7.60E-07 0.000154 BB229377 Mm.275320, elastin
Col1a1 -2.9436819 1.60E-07 4.83E-05 BI794771 Mm.277735 procollagen, type I, alpha 1
Col3a1 -2.6254093 6.91E-07 0.000144 BG075843 Mm.249555 procollagen, type III, alpha 1
Col11a1 -2.5613174 0.00011755 0.006237 NM_007729 Mm.209715 procollagen, type XI, alpha 1
Col5a2 -2.3009434 8.75E-09 4.93E-06 AV229424 Mm.10299 procollagen, type V, alpha 2
Eln -2.2686736 1.23E-08 6.43E-06 BB229377 Mm.275320, elastin
Col5a2 -2.2310021 6.31E-07 0.000134 AV229424 Mm.10299 procollagen, type V, alpha 2
Fbn1 -2.2188853 6.14E-09 3.74E-06 NM_007993 Mm.271644 fibrillin 1
Col4a5 -2.1432228 3.78E-07 9.03E-05 BM250666 Mm.286892 procollagen, type IV, alpha 5
Col11a1 -2.1242418 0.00045111 0.015402 NM_007729 Mm.209715 procollagen, type XI, alpha 1
Col5a3 -2.0269518 1.83E-06 0.000307 NM_016919 Mm.334994 procollagen, type V, alpha 3
Col4a3 -2.0197026 8.73E-05 0.005068 NM_007734 Mm.389135 procollagen, type IV, alpha 3
Fbn1 -1.9968533 3.12E-08 1.37E-05 AF007248 Mm.271644 fibrillin 1
Col4a3 -1.9927252 0.00066508 0.020131 AV366831 Mm.389135 procollagen, type IV, alpha 3
Fbln1 -1.9910311 0.0003049 0.011968 BC007140 Mm.297992 fibulin 1
Col1a2 -1.9752956 3.92E-05 0.002916 BB150460 Mm.277792 procollagen, type I, alpha 2
Col4a5 -1.9659698 6.34E-07 0.000134 BM250666 Mm.286892 procollagen, type IV, alpha 5
Col3a1 -1.9630329 9.64E-10 8.53E-07 AW550625 Mm.249555 procollagen, type III, alpha 1
Sparc -1.9372812 1.88E-08 9.21E-06 NM_009242 Mm.291442 secreted acidic cysteine rich glycoprotein
Sparc -1.9282242 3.2E-08 1.39E-05 NM_009242 Mm.291442 secreted acidic cysteine rich glycoprotein
Col5a1 -1.9075833 4.73E-05 0.003337 AW744319 Mm.7281 procollagen, type V, alpha 1
Col6a1 -1.8665417 8.34E-08 2.89E-05 NM_009933 Mm.2509 procollagen, type VI, alpha 1
Col9a1 -1.8332169 0.00064798 0.019854 AK004383 Mm.154662 procollagen, type IX, alpha 1
Col6a2 -1.8325502 9.13E-08 3.05E-05 BI455189 Mm.1949 procollagen, type VI, alpha 2
Col14a1 -1.8100671 1.68E-05 0.001563 BB521934 Mm.297859 procollagen, type XIV, alpha 1
Col1a2 -1.7775253 5.26E-09 3.30E-06 BF227507 Mm.277792 procollagen, type I, alpha 2
Col15a1 -1.7486951 1.15E-05 0.001213 AF011450 Mm.233547 procollagen, type XV
Col10a1 -1.7486624 0.00842435 0.106487 NM_009925 Mm.443177 procollagen, type X, alpha 1
Mmp2 -1.7453837 1.77E-06 0.000302 NM_008610 Mm.29564 matrix metallopeptidase 2
Col4a1 -1.741257 2.16E-07 6.17E-05 BF158638 Mm.738 procollagen, type IV, alpha 1
Fbln1 -1.7110513 0.00090112 0.024646 NM_010180 Mm.297992 fibulin 1
Col2a1 -1.6905208 0.00819705 0.104878 NM_031163 Mm.2423 procollagen, type II, alpha 1
Col4a6 -1.6892918 0.00054146 0.017569 BB794645 Mm.155586 procollagen, type IV, alpha 6
Mmp2 -1.6854596 9.07E-06 0.001 BF147716 Mm.29564 matrix metallopeptidase 2
Col6a2 -1.6838415 2.10E-06 0.000336 BI455189 Mm.1949 procollagen, type VI, alpha 2
Col5a1 -1.6635513 6.34E-06 0.00079 AW744319 Mm.7281 procollagen, type V, alpha 1
Col6a3 -1.6634733 1.32E-06 0.000239 AF064749 Mm.7562 procollagen, type VI, alpha 3
Mmp16 -1.6234235 0.00702838 0.096144 AF282844 Mm.204820 matrix metallopeptidase 16
Mmp14 -1.5735841 0.00022699 0.009806 NM_008608 Mm.280175 matrix metallopeptidase 14 (membrane-inserted)
Col4a2 -1.5601997 4.79E-05 0.003336 BC013560 Mm.181021 procollagen, type IV, alpha 2
Col4a1 -1.5557434 8.08E-05 0.004815 BF158638 Mm.738 procollagen, type IV, alpha 1
Col14a1 -1.5535355 4.16E-05 0.00301 AJ131395 Mm.297859 procollagen, type XIV, alpha 1
Col4a6 -1.4977489 0.00340145 0.060043 BB794645 Mm.155586 procollagen, type IV, alpha 6
Lamc1 -1.483957 0.0000757 0.004612 BG066605 Mm.1249 laminin, gamma 1
Col4a4 -1.4692681 0.0029215 0.054855 BB530633 Mm.40253, M  procollagen, type IV, alpha 4
Timp4 -1.4546069 0.00454159 0.072609 BI788452 Mm.255607 tissue inhibitor of metalloproteinase 4
Mmp14 -1.4037513 0.00214608 0.044604 NM_008608 Mm.280175 matrix metallopeptidase 14 (membrane-inserted)
Fbln5 -1.3734461 0.00075926 0.021909 NM_011812 Mm.288381 fibulin 5
Col19a1 1.96123182 3.39E-05 0.002587 BB459641 Mm.329196 procollagen, type XIX, alpha 1
Mmp9 1.99019903 0.00015219 0.007413 NM_013599 Mm.4406, Mmmatrix metallopeptidase 9
Mmp13 2.01744927 0.00843435 0.106494 NM_008607 Mm.5022 matrix metallopeptidase 13
Mmp9 2.04005973 5.36E-05 0.00361 NM_013599 Mm.4406, Mmmatrix metallopeptidase 9
Col19a1 2.25942133 4.84E-05 0.003349 NM_007733 Mm.329196 procollagen, type XIX, alpha 1
Mmp3 2.29322653 1.32E-08 6.78E-06 NM_010809 Mm.4993 matrix metallopeptidase 3
Mmp12 5.26819181 8.64E-08 2.95E-05 BC019135 Mm.2055 matrix metallopeptidase 12
Confirmed target of Mir29 (van Rooij et al PNAS (2008) 105, p13027-32)
Confirmed target of Mir29 (Li et al JBC (2009) 284, p15676-84)
Confirmed target of Mir29 (Luna Mol Vis (2009) 15, p2488-97)
Confirmed target of Mir29 (Liu Hypertension (2010) 55, p974-82)
Up in AAA (Rush et al BMC Gen (2009) 10, p298-314 and Pyo et al JCI (2000) 105, p1641-9)
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Online table III. Patient characteristics for the obtained aortic biopsies. 
 
 
 
 Control Bicuspid aortic 
valve + TAA 
Tricuspid aortic 
valve + TAA 
p-value 
n= 33 79 30  
Age 67.5(8.9) 58.3(12.3) 69(10.2) <0.0001 
Hypertension 70% 65% 80% 0.1905 
Angiotensin medication 58% 56% 14% 0.0120 
Hypercholesterolemia 42% 34% 27% 0.2442 
Diabetes 33% 6% 3% <0.0001 
Atrial fibrillation 3% 10% 20% 0.0776 
Smoker 30% 30% 17% 0.3715 
Females 18% 30% 52% 0.0067 
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